



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

12 August 2015
EMA/COMP/431519/2015
Committee for Orphan Medicinal Products

Public summary of opinion on orphan designation

Inecalcitol for the treatment of acute myeloid leukaemia

On 28 July 2015, orphan designation (EU/3/15/1523) was granted by the European Commission to Hybrigenics SA, France, for inecalcitol for the treatment of acute myeloid leukaemia.

What is acute myeloid leukaemia?

Acute myeloid leukaemia (AML) is a cancer of the white blood cells (cells that fight against infections). In patients with AML, the bone marrow (the spongy tissue inside the large bones, where blood cells are produced) produces large numbers of abnormal, immature white blood cells. These abnormal cells quickly build up in large numbers in the bone marrow and are found in the blood.

AML is a long-term debilitating and life-threatening disease because these abnormal immature cells take the place of the normal blood cells, causing bleeding episodes, blood clots and reducing the patient's ability to fight infections.

What is the estimated number of patients affected by the condition?

At the time of designation, AML affected less than 1 in 10,000 people in the European Union (EU). This was equivalent to a total of fewer than 51,000 people^{*}, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

What treatments are available?

Treatment for AML is complex and depends on a number of factors including the extent of the disease, whether it has been treated before, and the patient's age, symptoms and general state of health. At the time of designation, the main treatments for AML were chemotherapy (medicines to treat cancer) and haematopoietic (blood) stem-cell transplantation (a complex procedure where the patient receives stem cells from a matched donor to help restore the bone marrow).

^{*}Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 512,900,000 (Eurostat 2015).



The sponsor has provided sufficient information to show that inecalcitol might be of significant benefit for patients with AML, with data from animal studies indicating that the medicine may improve survival when used in combination with medicines known as demethylating agents. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.

How is this medicine expected to work?

Inecalcitol is a type of vitamin D (a 'vitamin D analogue') and attaches to the vitamin D receptor which is involved in turning genes 'on' and 'off' within cells. In AML, inecalcitol is expected to switch 'on' the genes that suppress the division and growth of the cancer cells and to switch 'off' those genes that stimulate the division and growth of the cancer cells. This is expected to lead to a reduction in the growth and division of the cancer cells, thereby slowing the progression of the disease.

What is the stage of development of this medicine?

The effects of inecalcitol have been evaluated in experimental models.

At the time of submission of the application for orphan designation, no clinical trials with inecalcitol in patients with AML had been started.

At the time of submission, inecalcitol was not authorised anywhere in the EU for AML or designated as an orphan medicinal product elsewhere for this condition.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 18 June 2015 recommending the granting of this designation.

Opinions on orphan medicinal product designations are based on the following three criteria:

- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

For more information

Sponsor's contact details:

Hybrigenics SA
3-5 impasse Reille
75014 Paris
France
Tel. +33 1 58 10 38 00 08
Fax +33 1 58 10 38 40
E-mail: inecalcitol@hybrigenics.com

For contact details of patients' organisations whose activities are targeted at rare diseases see:

- [Orphanet](#), a database containing information on rare diseases, which includes a directory of patients' organisations registered in Europe;
- [European Organisation for Rare Diseases \(EURORDIS\)](#), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

Translations of the active ingredient and indication in all official EU languages¹, Norwegian and Icelandic

Language	Active ingredient	Indication
English	Inecalcitol	Treatment of acute myeloid leukaemia
Bulgarian	Инекалцитол	Лечение на остра миелоидна левкемия
Croatian	Inecalcitol	Liječenje akutne mijeloične leukemije
Czech	Inecalcitol	Léčba akutní myeloidní leukémie
Danish	Inecalcitol	Behandling af akut myeloid leukæmi
Dutch	Inecalcitol	Behandeling van acute myeloïde leukemie
Estonian	Inecalcitol	Akuutse müeloidse leukeemia ravi
Finnish	Inekalsitoli	Akuutin myelooisen leukemian hoito
French	Inecalcitol	Traitement de la leucémie aiguë myéloïde
German	Inecalcitol	Behandlung der akuten myeloischen Leukämie
Greek	Ινεκαλσιτόλη	Θεραπεία της οξείας μυελοειδούς λευχαιμίας
Hungarian	Inecalcitol	Akut myeloid leukaemia kezelése
Italian	Inecalcitol	Trattamento della leucemia mieloide acuta
Latvian	Inekalcitols	Akūtas mieloleikozes ārstēšana
Lithuanian	Inekalcitolis	Ūmios mieloleukozės gydymas
Maltese	Inecalcitol	Kura tal-lewkimja mjelojda akuta
Polish	Inekalcitol	Leczenie ostrej białaczki szpikowej
Portuguese	Inecalcitol	Tratamento da leucémia mieloide aguda
Romanian	Inecalcitol	Tratamentul leucemiei mieloide acute
Slovak	Inekalcitol	Liečba akútnej myeloickej leukémie
Slovenian	Inekalcitol	Zdravljenje akutne mieloične levkemije
Spanish	Inecalcitol	Tratamiento de la leucemia mieloide aguda
Swedish	Inecalcitol	Behandling av akut myeloisk leukemi
Norwegian	Inekalsitol	Behandling av akutt myelogen leukemi
Icelandic	Ínekalsitól	Meðferð við bráðu kyrningahvítblæði

¹ At the time of designation